FI3846903T3 - Bisyklisiä hereoaryylijohdannaisia - Google Patents
Bisyklisiä hereoaryylijohdannaisia Download PDFInfo
- Publication number
- FI3846903T3 FI3846903T3 FIEP19759411.2T FI19759411T FI3846903T3 FI 3846903 T3 FI3846903 T3 FI 3846903T3 FI 19759411 T FI19759411 T FI 19759411T FI 3846903 T3 FI3846903 T3 FI 3846903T3
- Authority
- FI
- Finland
- Prior art keywords
- amine
- azabicyclo
- octan
- triazolo
- tetrahydro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- RETFIEPIZUQCDL-UHFFFAOYSA-N oxazin-2-amine Chemical compound NN1OC=CC=C1 RETFIEPIZUQCDL-UHFFFAOYSA-N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- AZYDDVMRBOBLAB-RJNPCAAESA-N CC1=CC(=NC=N1)N1C[C@H]2CC[C@@H](C1)C2NC2=NN1C([C@@H](OCC1)C1=C(C(=C(C=C1)F)F)F)=N2 Chemical compound CC1=CC(=NC=N1)N1C[C@H]2CC[C@@H](C1)C2NC2=NN1C([C@@H](OCC1)C1=C(C(=C(C=C1)F)F)F)=N2 AZYDDVMRBOBLAB-RJNPCAAESA-N 0.000 claims 2
- BJIRZELARKXLRV-GHEUYMLLSA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4F)=C4F)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4F)=C4F)C3=N2)=NC=N1 BJIRZELARKXLRV-GHEUYMLLSA-N 0.000 claims 2
- PUVJNVLOUNIHNF-MFGZZSJASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 PUVJNVLOUNIHNF-MFGZZSJASA-N 0.000 claims 2
- FECROEMXGDFEFX-MFGZZSJASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=NC=N1 FECROEMXGDFEFX-MFGZZSJASA-N 0.000 claims 2
- BJIRZELARKXLRV-DIMRZHFKSA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4F)=C4F)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4F)=C4F)C3=N2)=NC=N1 BJIRZELARKXLRV-DIMRZHFKSA-N 0.000 claims 2
- FECROEMXGDFEFX-MVGGYSAASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=NC=N1 FECROEMXGDFEFX-MVGGYSAASA-N 0.000 claims 2
- QPLPWZUDACSPEY-MYICOXDBSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4F)=C4F)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4F)=C4F)C3=N2)=CN=N1 QPLPWZUDACSPEY-MYICOXDBSA-N 0.000 claims 2
- DRMLDDBQPBECRA-GHEUYMLLSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 DRMLDDBQPBECRA-GHEUYMLLSA-N 0.000 claims 2
- DRMLDDBQPBECRA-DIMRZHFKSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 DRMLDDBQPBECRA-DIMRZHFKSA-N 0.000 claims 2
- QFLMYOYPGVRLER-UISQCYCNSA-N COC1=NC=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=C1 Chemical compound COC1=NC=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=C1 QFLMYOYPGVRLER-UISQCYCNSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Chemical group 0.000 claims 2
- 239000000460 chlorine Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- OUMFVKNEDMFGII-GHEUYMLLSA-N (8R)-8-(3-chloro-5-fluorophenyl)-N-[(1R,5S)-3-(2-methoxypyridin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-amine Chemical compound ClC=1C=C(C=C(C=1)F)[C@H]1OCCN2C1=NC(=N2)NC1[C@H]2CN(C[C@@H]1CC2)C1=CC(=NC=C1)OC OUMFVKNEDMFGII-GHEUYMLLSA-N 0.000 claims 1
- DMNYTRIALSCYSN-VUBXYBDHSA-N (8R)-8-(3-chloro-5-fluorophenyl)-N-[(1R,5S)-3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-amine Chemical compound ClC=1C=C(C=C(C=1)F)[C@H]1OCCN2C1=NC(=N2)NC1[C@H]2CN(C[C@@H]1CC2)C1=NC=NC(=C1)C DMNYTRIALSCYSN-VUBXYBDHSA-N 0.000 claims 1
- OUMFVKNEDMFGII-DIMRZHFKSA-N (8S)-8-(3-chloro-5-fluorophenyl)-N-[(1R,5S)-3-(2-methoxypyridin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-amine Chemical compound ClC=1C=C(C=C(C=1)F)[C@@H]1OCCN2C1=NC(=N2)NC1[C@H]2CN(C[C@@H]1CC2)C1=CC(=NC=C1)OC OUMFVKNEDMFGII-DIMRZHFKSA-N 0.000 claims 1
- SSQYSSOQTRMADE-RJNPCAAESA-N (8S)-8-(3-chloro-5-fluorophenyl)-N-[(1R,5S)-3-(6-methoxypyridazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-amine Chemical compound ClC=1C=C(C=C(C=1)F)[C@@H]1OCCN2C1=NC(=N2)NC1[C@H]2CN(C[C@@H]1CC2)C1=CN=NC(=C1)OC SSQYSSOQTRMADE-RJNPCAAESA-N 0.000 claims 1
- KPYSGXUTUVOMIM-WEBFOWBXSA-N (9R)-N-[(1R,5S)-3-(2-methoxypyridin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-9-(2,3,4-trifluorophenyl)-5,6,7,9-tetrahydro-[1,2,4]triazolo[5,1-c][1,4]oxazepin-2-amine Chemical compound COC1=NC=CC(=C1)N1C[C@H]2CC[C@@H](C1)C2NC1=NN2C([C@H](OCCC2)C2=C(C(=C(C=C2)F)F)F)=N1 KPYSGXUTUVOMIM-WEBFOWBXSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- TZHWRCJKZZSICY-MFGZZSJASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4)=C4F)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4)=C4F)C3=N2)=NC=N1 TZHWRCJKZZSICY-MFGZZSJASA-N 0.000 claims 1
- SLOCFYCPEIIVMG-MFGZZSJASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC=C4F)=C4F)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC=C4F)=C4F)C3=N2)=NC=N1 SLOCFYCPEIIVMG-MFGZZSJASA-N 0.000 claims 1
- WXBDNKUJROQEHZ-MFGZZSJASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(F)=CC(F)=C4)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(F)=CC(F)=C4)C3=N2)=NC=N1 WXBDNKUJROQEHZ-MFGZZSJASA-N 0.000 claims 1
- TZHWRCJKZZSICY-MVGGYSAASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4)=C4F)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4)=C4F)C3=N2)=NC=N1 TZHWRCJKZZSICY-MVGGYSAASA-N 0.000 claims 1
- SLOCFYCPEIIVMG-MVGGYSAASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC=C4F)=C4F)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC=C4F)=C4F)C3=N2)=NC=N1 SLOCFYCPEIIVMG-MVGGYSAASA-N 0.000 claims 1
- WXBDNKUJROQEHZ-MVGGYSAASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(F)=CC(F)=C4)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(F)=CC(F)=C4)C3=N2)=NC=N1 WXBDNKUJROQEHZ-MVGGYSAASA-N 0.000 claims 1
- DZUYPIUHOTVGEZ-ZPGWGORSSA-N COC1=CC(=CN=N1)N1C[C@H]2CC[C@@H](C1)C2NC2=NN1C([C@H](OCC1)C1=C(C(=C(C=C1)F)F)F)=N2 Chemical compound COC1=CC(=CN=N1)N1C[C@H]2CC[C@@H](C1)C2NC2=NN1C([C@H](OCC1)C1=C(C(=C(C=C1)F)F)F)=N2 DZUYPIUHOTVGEZ-ZPGWGORSSA-N 0.000 claims 1
- KQQKMJRXNXRLPN-GHEUYMLLSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4)=C4F)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4)=C4F)C3=N2)=CN=N1 KQQKMJRXNXRLPN-GHEUYMLLSA-N 0.000 claims 1
- WGNAEOBGKQHHBW-GHEUYMLLSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(F)=CC(F)=C4)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(F)=CC(F)=C4)C3=N2)=CN=N1 WGNAEOBGKQHHBW-GHEUYMLLSA-N 0.000 claims 1
- KQQKMJRXNXRLPN-DIMRZHFKSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4)=C4F)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4)=C4F)C3=N2)=CN=N1 KQQKMJRXNXRLPN-DIMRZHFKSA-N 0.000 claims 1
- KPYSGXUTUVOMIM-DWTVLSKDSA-N COC1=NC=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4F)=C4F)C3=N2)=C1 Chemical compound COC1=NC=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4F)=C4F)C3=N2)=C1 KPYSGXUTUVOMIM-DWTVLSKDSA-N 0.000 claims 1
- QFLMYOYPGVRLER-GUNXFRPYSA-N COC1=NC=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=C1 Chemical compound COC1=NC=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=C1 QFLMYOYPGVRLER-GUNXFRPYSA-N 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- DMNYTRIALSCYSN-VCTRGTQWSA-N ClC=1C=C(C=C(C1)F)[C@@H]1OCCN2C1=NC(=N2)NC2[C@H]1CN(C[C@@H]2CC1)C1=NC=NC(=C1)C Chemical compound ClC=1C=C(C=C(C1)F)[C@@H]1OCCN2C1=NC(=N2)NC2[C@H]1CN(C[C@@H]2CC1)C1=NC=NC(=C1)C DMNYTRIALSCYSN-VCTRGTQWSA-N 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- 208000017004 dementia pugilistica Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000012907 medicinal substance Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18192219 | 2018-09-03 | ||
| PCT/EP2019/073303 WO2020048904A1 (en) | 2018-09-03 | 2019-09-02 | Bicyclic heteroaryl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3846903T3 true FI3846903T3 (fi) | 2023-12-19 |
Family
ID=63490310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19759411.2T FI3846903T3 (fi) | 2018-09-03 | 2019-09-02 | Bisyklisiä hereoaryylijohdannaisia |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US12084461B2 (he) |
| EP (1) | EP3846903B1 (he) |
| JP (1) | JP7398435B2 (he) |
| KR (1) | KR20210054515A (he) |
| CN (1) | CN112566696B (he) |
| AR (1) | AR116051A1 (he) |
| BR (1) | BR112021002170A2 (he) |
| CA (1) | CA3107593A1 (he) |
| CL (1) | CL2021000486A1 (he) |
| CO (1) | CO2021002415A2 (he) |
| CR (1) | CR20210104A (he) |
| DK (1) | DK3846903T3 (he) |
| ES (1) | ES2966947T3 (he) |
| FI (1) | FI3846903T3 (he) |
| HR (1) | HRP20231663T1 (he) |
| HU (1) | HUE064554T2 (he) |
| IL (1) | IL281175B2 (he) |
| LT (1) | LT3846903T (he) |
| MA (1) | MA53541B1 (he) |
| MX (1) | MX2021002087A (he) |
| PE (1) | PE20210860A1 (he) |
| PH (1) | PH12021550320A1 (he) |
| PL (1) | PL3846903T3 (he) |
| PT (1) | PT3846903T (he) |
| RS (1) | RS64950B1 (he) |
| SG (1) | SG11202102137SA (he) |
| SI (1) | SI3846903T1 (he) |
| TW (1) | TWI841592B (he) |
| UA (1) | UA128482C2 (he) |
| WO (1) | WO2020048904A1 (he) |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994349A (en) | 1997-10-27 | 1999-11-30 | Howard University | 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives |
| ES2217742T3 (es) | 1998-04-01 | 2004-11-01 | Cardiome Pharma Corp. | Compuestos de amino ciclohexil eter y usos del mismo. |
| WO2000047547A2 (en) | 1999-02-12 | 2000-08-17 | Nortran Pharmaceuticals Inc. | Cycloalkyl amine compounds and uses thereof |
| US7507545B2 (en) | 1999-03-31 | 2009-03-24 | Cardiome Pharma Corp. | Ion channel modulating activity method |
| WO2000071528A1 (en) | 1999-05-25 | 2000-11-30 | Neurogen Corporation | 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands |
| WO2001032170A1 (en) | 1999-09-13 | 2001-05-10 | Swope David M | Composition and method for decreasing neurologic symptomatology |
| US7057053B2 (en) | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
| WO2007032009A2 (en) | 2005-09-15 | 2007-03-22 | Biomas Ltd. | Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis |
| BRPI0811993A2 (pt) | 2007-05-11 | 2014-11-18 | Hoffmann La Roche | " hetarilanilinas como moduladores para beta-amiloide ". |
| ATE543799T1 (de) | 2007-10-19 | 2012-02-15 | Janssen Pharmaceutica Nv | Piperidinyl- und piperazinylmodulatoren von g- sekretase |
| MX2011005046A (es) | 2008-11-13 | 2011-06-01 | Schering Corp | Moduladores de gamma secretasa. |
| NZ594776A (en) | 2009-02-26 | 2013-05-31 | Eisai R&D Man Co Ltd | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
| WO2010138901A1 (en) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
| WO2011028208A1 (en) | 2009-09-04 | 2011-03-10 | Hewlett-Packard Development Company, L.P. | Memristors based on mixed-metal-valence compounds |
| JPWO2011007756A1 (ja) * | 2009-07-13 | 2012-12-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| CN103874702B (zh) | 2011-07-15 | 2015-12-09 | 杨森制药公司 | 作为γ分泌酶调节剂的经取代的吲哚衍生物 |
| WO2014060112A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| WO2017042114A1 (en) | 2015-09-09 | 2017-03-16 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| CN108137579B (zh) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| WO2018001918A1 (en) | 2016-06-27 | 2018-01-04 | F. Hoffmann-La Roche Ag | Triazolopyridines as gamma-secretase modulators |
| AR109829A1 (es) | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| WO2018083050A1 (en) * | 2016-11-01 | 2018-05-11 | F. Hoffmann-La Roche Ag | Bicyclic heteroaryl derivatives |
| CN109790149B (zh) | 2016-11-08 | 2022-05-17 | 豪夫迈·罗氏有限公司 | 苯氧基三唑类化合物 |
| RU2757276C2 (ru) | 2016-12-16 | 2021-10-12 | Пайплайн Терапьютикс, Инк. | Способы лечения кохлеарной синаптопатии |
| US11370802B2 (en) | 2018-01-22 | 2022-06-28 | Hoffmann-La Roche, Inc. | Triazolo-azepine derivatives |
-
2019
- 2019-09-02 US US17/273,278 patent/US12084461B2/en active Active
- 2019-09-02 MX MX2021002087A patent/MX2021002087A/es unknown
- 2019-09-02 HR HRP20231663TT patent/HRP20231663T1/hr unknown
- 2019-09-02 CN CN201980054254.2A patent/CN112566696B/zh active Active
- 2019-09-02 SG SG11202102137SA patent/SG11202102137SA/en unknown
- 2019-09-02 KR KR1020217006240A patent/KR20210054515A/ko unknown
- 2019-09-02 SI SI201930682T patent/SI3846903T1/sl unknown
- 2019-09-02 BR BR112021002170-1A patent/BR112021002170A2/pt unknown
- 2019-09-02 HU HUE19759411A patent/HUE064554T2/hu unknown
- 2019-09-02 PT PT197594112T patent/PT3846903T/pt unknown
- 2019-09-02 PE PE2021000165A patent/PE20210860A1/es unknown
- 2019-09-02 PL PL19759411.2T patent/PL3846903T3/pl unknown
- 2019-09-02 UA UAA202101190A patent/UA128482C2/uk unknown
- 2019-09-02 WO PCT/EP2019/073303 patent/WO2020048904A1/en active Application Filing
- 2019-09-02 TW TW108131458A patent/TWI841592B/zh active
- 2019-09-02 IL IL281175A patent/IL281175B2/he unknown
- 2019-09-02 FI FIEP19759411.2T patent/FI3846903T3/fi active
- 2019-09-02 ES ES19759411T patent/ES2966947T3/es active Active
- 2019-09-02 JP JP2021512272A patent/JP7398435B2/ja active Active
- 2019-09-02 EP EP19759411.2A patent/EP3846903B1/en active Active
- 2019-09-02 MA MA53541A patent/MA53541B1/fr unknown
- 2019-09-02 RS RS20231189A patent/RS64950B1/sr unknown
- 2019-09-02 CR CR20210104A patent/CR20210104A/es unknown
- 2019-09-02 AR ARP190102494A patent/AR116051A1/es unknown
- 2019-09-02 LT LTEPPCT/EP2019/073303T patent/LT3846903T/lt unknown
- 2019-09-02 DK DK19759411.2T patent/DK3846903T3/da active
- 2019-09-02 CA CA3107593A patent/CA3107593A1/en active Pending
-
2021
- 2021-02-15 PH PH12021550320A patent/PH12021550320A1/en unknown
- 2021-02-24 CO CONC2021/0002415A patent/CO2021002415A2/es unknown
- 2021-02-26 CL CL2021000486A patent/CL2021000486A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018282154B2 (en) | Compounds for treating huntington's disease | |
| JP7515415B2 (ja) | ハンチントン病を処置するためのヘテロアリール化合物 | |
| US11395822B2 (en) | Methods for treating Huntington's disease | |
| CA2954189A1 (en) | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof | |
| HRP20151071T1 (hr) | Spojevi pirolopirimidina kao inhibitori za cdk4/6 | |
| DK1966200T3 (en) | Heterocyclic JANUS kinase 3 inhibitors | |
| EP3814360A1 (en) | Heteroaryl compounds for treating huntington's disease | |
| JP2005508932A5 (he) | ||
| JPWO2019191092A5 (he) | ||
| RU2008110488A (ru) | Мостиковые n-бициклические сульфонамиды, являющиеся ингибиторами гамма-секретазы | |
| HUE033099T2 (en) | New tricyclic compounds | |
| JP2014513139A5 (he) | ||
| AU2012302011A1 (en) | Antibacterial compounds and methods for use | |
| NZ590922A (en) | Piperidine derivatives as jak3 inhibitors | |
| WO2013042035A4 (en) | Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections | |
| JP2023522177A (ja) | ハンチントン病を処置するための化合物 | |
| TW201632533A (zh) | 抗肺結核病的硝基咪唑衍生物 | |
| FI3846903T3 (fi) | Bisyklisiä hereoaryylijohdannaisia | |
| JP2016517877A5 (he) | ||
| RU2021108939A (ru) | Бициклические гетероарильные производные | |
| CN106946909A (zh) | 抗肺结核病的硝基咪唑衍生物 | |
| FI3894411T3 (fi) | 7-fenoksi-n-(3-atsabisyklo[3.2.1]oktan-8-yyli)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triatsoli-2-amiinijohdannaisia ja niihin liittyviä yhdisteitä gammasekretaasin modulaattoreina alzheimerin taudin hoitoon | |
| RU2021118626A (ru) | Производные 7-фенокси-n-(3-азабицикло[3.2.1]октан-8-ил)-6,7-дигидро-5h-пирроло[1,2-b][1,2,4]триазол-2-амина и связанные соединения в качестве модуляторов гамма-секретазы для лечения болезни альцгеймера | |
| EA045014B1 (ru) | Гетероарильные соединения для лечения болезни гентингтона | |
| EA043655B1 (ru) | Соединения для лечения болезни хантингтона |